文献速递真菌感染细菌感染、耐药与抗菌药物

烟曲霉三唑类耐药:最新见解与患者管理挑战

Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management.
PubMed 文献 · Clin Microbiol Infect · 2018-12-21

综述指出烟曲霉三唑类耐药广泛存在,威胁曲霉病一线三唑治疗。耐药通过Cyp51A基因突变在选择压力下产生,不同国家与医院耐药率差异大。耐药侵袭性曲霉病患者第42天死亡率较敏感感染者高21%,需一线覆盖耐药的治疗。ESCMID-ECMM-ERS指南推荐进行耐药检测和当地监测,耐药率超过10%时考虑脂质体两性霉素B或三唑联合棘白菌素一线治疗。

要点

  • 烟曲霉三唑类耐药广泛存在,显著威胁曲霉病一线三唑治疗。
  • 耐药侵袭性曲霉病第42天死亡率较敏感感染高21%,需一线覆盖耐药。
  • 指南推荐耐药检测与当地监测,耐药率超10%考虑脂质体两性霉素B或三唑联合棘白菌素。

核心结论

  • 烟曲霉三唑类耐药显著复杂化曲霉病管理,需从「同一健康」视角开展多学科研究以保留三唑类医疗用途。

研究设计与样本

  • 通过PubMed检索烟曲霉耐药相关文献的综述,涵盖微生物学、流行病学与临床意义。

主要发现

  • 三唑类非诱变剂,但自发突变在选择压力下可导致耐药,主要靶点为Cyp51A基因。
  • 耐药选择环境包括患者治疗和含三唑类杀菌剂残留的有机物。
  • 不同国家与医院报告的耐药频率差异很大,耐药显著复杂化诊断与治疗。
  • 培养可能包含多种耐药表型,需分析多个菌落以检测耐药。
  • PCR检测可用于培养阴性患者的耐药检测,但敏感性有限。

关键数值与推荐

  • 耐药侵袭性曲霉病患者第42天死亡率较三唑敏感感染高21%。
  • ESCMID-ECMM-ERS曲霉指南推荐对烟曲霉进行耐药检测和当地耐药监测。
  • 若耐药率超过10%,应考虑脂质体两性霉素B或三唑联合棘白菌素一线治疗。

临床怎么用

  • 对曲霉病患者应进行烟曲霉耐药检测,并开展当地耐药监测。
  • 耐药率超过10%时,一线治疗应考虑脂质体两性霉素B或三唑联合棘白菌素。
  • 培养阳性时需分析多个菌落以检出耐药表型。

局限性

  • PCR耐药检测在培养阴性患者中敏感性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triazole resistance in Aspergillus fumigatus is widespread and threatens first-line triazole therapy in patients with Aspergillus diseases. OBJECTIVES: To give an overview of the microbiology, epidemiology and clinical significance of triazole resistance in aspergillosis. SOURCES: PubMed search for articles on resistance in Aspergillus species. CONTENT: Triazoles are not mutagenic but select resistance when spontaneous mutations occur that are better able to proliferate in the triazole-containing environment. The major target for resistance mutations involves the Cyp51A gene, encoding an enzyme involved in cell wall synthesis. Triazole-resistance selection environments include patient treatment and organic matter containing triazole fungicide residues. Reported resistance frequencies vary widely between countries and hospitals, and resistance significantly complicates the diagnosis and treatment of Aspergillus diseases. Cultures may harbour various resistance phenotypes and multiple colonies must be analysed to detect resistance. PCR tests have become available for resistance detection in culture-negative patients, but show limited sensitivity. Individuals with triazole-resistant invasive aspergillosis have a 21% higher day-42 mortality compared with triazole-susceptible infection, and to prevent excess mortality resistant cases require first-line therapy that covers resistance. The recent ESCMID-ECMM-ERS Aspergillus guideline recommends resistance testing in A. fumigatus and local resistance surveillance. If resistance rates exceed 10% liposomal amphotericin B or triazole and echinocandin first-line therapy should be considered. IMPLICATIONS: Triazole resistance significantly complicates the management of aspergillosis and multidisciplinary research from a 'One-health' perspective is required to retain the triazole class for medical use.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Lestrade PPA, Meis JF, Melchers WJG, et al. Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clin Microbiol Infect. 2018. PMID: 30580035. doi:10.1016/j.cmi.2018.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。